Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Results: Oral semaglutide reduced HbA1c levels compared to placebo Oral semaglutide patients experienced significant weight loss compared to those on placebo The primary outcome (composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) occurred in 3.8% of patients in the oral semaglutide group and 4.8% in the placebo group, which showed that cardiovascular safety of oral semaglutide was non-inferior to placebo
10.1016/j.ajog.2025.04.011 36 IbrahimI
Conclusions We identified the causal role of GLP-1R-based agonists in reducing the risk of MASLD and its complications, probably by improving systemic metabolic disorders and partly independent of their weight-loss effect
Sajdel-Sulkowska EM, Xu M, McGinnis W, Koibuchi N
